GLP-1 Weight-Loss Listings: Check Product Status and Pharmacy

A U.S.-specific checklist for distinguishing FDA-approved medicines from compounded listings and checking product and pharmacy details.

Start by identifying the product status

An FDA-approved medicine and a compounded drug are different product categories. FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. Compounding may be appropriate when an individual patient’s medical need cannot be met by an FDA-approved drug or that drug is not commercially available; it does not make a compounded product a generic version of an approved medicine.

In March 2026, FDA warned telehealth companies about claims that implied compounded GLP-1 products were the same as approved medicines and about promotions that obscured product sourcing. A company logo on the page does not identify the pharmacy that dispenses or compounds a product.

Verify the prescriber and pharmacy

1. Look for a prescription and an assessment by a licensed health professional.
2. Find the dispensing pharmacy’s legal name and contact details on the listing and product information.
3. Check the pharmacy’s license with the relevant state board, using FDA’s BeSafeRx online-pharmacy resources.
4. Confirm that a licensed pharmacist is available to answer product questions.

A medicine sold without a prescription or screening, a missing pharmacy identity, or a claim that a compounded drug is FDA-approved deserves a pause. If any of these details are unclear, ask the prescribing clinician or pharmacist before relying on the listing.

Read the ingredient and formulation literally

Record the exact active ingredient, dosage form, route, and package presentation shown. Do not infer that products are interchangeable from similar names, prices, or photographs. FDA states that semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide used in approved drugs, and says it does not know whether those salt forms have the same properties.

Listings for research-use products or unapproved ingredients should not be treated as ordinary prescription listings. FDA’s current GLP-1 information also explains that compounded drugs are not approved and summarizes current concerns. Recheck that page when evaluating a listing because regulatory information can change.

Compare price only after identity

Once the product type and package are clear, record the package price separately from consultation, membership, dispensing, and delivery fees. A lower price does not establish approval, quality, or equivalence. SuppScan displays package information; it does not select treatment or tell a reader which product to use.

Frequently asked questions

Is a compounded GLP-1 a generic medicine?

No. FDA says compounded drugs are not FDA-approved and are not the same as FDA-approved generic drugs. Do not infer equivalence from a marketing claim.

Does a telehealth company name show who made the medicine?

No. Check the pharmacy or compounder named in the product information and verify the dispensing pharmacy’s license.

Can I compare a compounded product and an approved medicine by price?

You can record each package price, but the two listings are not equivalent product comparisons. Keep their status, formulation, and dispensing context visible and do not use price to decide suitability.

Sources and review

Sources: FDA, concerns with unapproved GLP-1 drugs; FDA, March 2026 warning to telehealth companies; FDA, April 2026 compounding-policy clarification; FDA, BeSafeRx. Reviewed September 28, 2026. U.S.-specific product information; not medical advice.

Use current SuppScan data

SuppScan presents the product data available in its catalog and does not manufacture missing values. Open the Weight-management medications comparison to review current offers and normalized metrics.